News | September 07, 2023
Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar
First of its kind screening for Glaucoma at grass root level over 10k screened already
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Women of all ages will get round-the-clock access to comprehensive treatment
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Honan will lead the company in identifying and executing acquisitions that complement Emmes’ existing strong federal government client base, expand its biopharma portfolio, enhance its technology offerings, and broaden its global reach
LG Chem will receive totaling up to $95.5 million for the China rights
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
Subscribe To Our Newsletter & Stay Updated
